Yousif Capital Management LLC Has $902,000 Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Yousif Capital Management LLC lessened its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 5.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 53,649 shares of the biopharmaceutical company’s stock after selling 3,164 shares during the quarter. Yousif Capital Management LLC’s holdings in Catalyst Pharmaceuticals were worth $902,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of CPRX. SG Americas Securities LLC bought a new position in Catalyst Pharmaceuticals in the third quarter valued at approximately $502,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Catalyst Pharmaceuticals by 25.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,692 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 5,044 shares during the period. Assetmark Inc. lifted its stake in Catalyst Pharmaceuticals by 11.1% in the third quarter. Assetmark Inc. now owns 62,173 shares of the biopharmaceutical company’s stock valued at $727,000 after buying an additional 6,218 shares during the period. Teacher Retirement System of Texas boosted its holdings in Catalyst Pharmaceuticals by 5.3% during the third quarter. Teacher Retirement System of Texas now owns 28,682 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 1,456 shares during the last quarter. Finally, LSV Asset Management grew its position in shares of Catalyst Pharmaceuticals by 25.6% during the 3rd quarter. LSV Asset Management now owns 1,240,769 shares of the biopharmaceutical company’s stock worth $14,505,000 after buying an additional 253,100 shares during the period. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total transaction of $411,000.00. Following the completion of the sale, the insider now directly owns 124,433 shares in the company, valued at $2,045,678.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 11.00% of the stock is currently owned by insiders.

Catalyst Pharmaceuticals Stock Down 2.0 %

CPRX opened at $14.72 on Friday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $11.09 and a 12-month high of $17.76. The business has a 50 day moving average of $15.65 and a 200-day moving average of $14.70. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of 24.13, a PEG ratio of 0.83 and a beta of 0.89.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.04. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. The business had revenue of $110.57 million during the quarter, compared to the consensus estimate of $105.78 million. As a group, analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CPRX. HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. Oppenheimer reissued an “outperform” rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. Citigroup initiated coverage on Catalyst Pharmaceuticals in a report on Thursday, March 14th. They issued a “buy” rating and a $27.00 price objective for the company. TheStreet upgraded Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $34.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $26.43.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.